Ambra Maddalon, Giulia Leonetti, Sophie Zimmer
3D bioprinting has the potential to provide nonanimal alternatives to preclinical testing and revolutionize current clinical and transplantation practices. Realizing this potential requires a concerted effort to develop and advance European standards and regulatory frameworks, ensuring a clear and safe pathway for the clinical integration of 3D bioprinting.